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Summary, future perspectives and
conclusions L2
As the male popularion ases, the incidence of prostate c.lncer is expected to
increase further, with many consequences including an increased burden
for the health care svsrern. The i.cidence lras risen steadily cluri.g thc pasr
1 0 - 1 5 years. Part of th is increase is l ikely to be real but in.rprovecl
ascertainment of cancer cases by the regisrr-ies, and improved and earlier
diagnostic accuracy will also have contributed towards the increase.
In the Nerherlands prosrare cancer has been diagnosed in approximarely
6400 cases each year-. In I 995, the incidence was 84 per 100.000 men.
Prostate callcer is the second most frequenr cause of cancer death in the
Netherlands with a mortality of approxim ately 2425 men per year (1).
This has encouraged investigatior-r of screening, earlier detectior.r and
culative therapy for prostate cancer.
Since early srage prosrare cancer can be treated cffectivelv, early detection
programs have becn introduced. In the late l9Í10's rhe docurnented
incidcnce of prosrare carcinoma rose dramarically probably due to the
introductio' of these early detecrion program.s consisting of digital rectal
examination (DRE), serum prosrate-specifi c antigen (PSA) determir-rations
and transrectal ultrasonography (TRUS)(2). Whether prosrare cancer
screening can save iives :rnd be economical is sri l l  uncertain rud r-rnder
investigation in large srLrdie-s both in rhe USA and ir.r Eur-ope (3).
This thesis evaluares ome recenr diag'osric advances of biochemical and
clinical lactors in prostare cancer and the currenr and potential future role
of some of the :rvailable markers for prost:rte cancer.
Chapter 2 was, initially, written for the general-practitioner and it reviews
the literature of prostate cancer. contemporary developments of prostate
càncer syrnproms, - screening, -diagnosis :rnd staging are given in this
chapter. Further'rore, a revierv of the l iterature about curative treatment
for locally prostare cancer is given rogerher with a summary of possible
palliative and hormonal treatmenrs for advanced and metastatic
citrcinoma. Some of the tbllowing pracrical points :rre oÍrinreresr:
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- By the use ofprostate-specific antigen, the use oftransrectal ultrasound,
the growing 2lwareness of prostatic disease and the prevalence of
prostate cancer, an incre:rse in the detection of patients with clinically
localized tumors (with the greatest potendal for cure) may be expected
in the next decades.
- Candidates for curative treatment are parients with a T1- and T2
c:rrcinoma of rhe prostate; these tumors do not invade or break through
the prostatic capsule and give less con.rplaints or symptoms.
- An asymptomatic prostate cancer may be detected with digital rectal
examination and / or a prostate-specific antigen (PSA) determination.
- Adenocarcinoma of the prosrate usually (70o/o) arises within the
peripheral zone of the prostate; the remaining30o/o develop in the
transition- and central zor-re of the prostate and are in this region not
palpable by digital rectal examination.
- Alkaline Phosphatase (ALP) remains a reli,rble prognostic indicator of
osteoblastic activity in prostate cancer with bone metastasis while serum
PSA levels are to a large extend proportional to tumor volume and
clinical stage.
- Medical trern.nent (> 6 monrhs) for benign prostatic hvperplasia with a
5-alpha-reductase inhibitor, such as finasteride, can reduce serum PSA-
concentration levels (more than 50%o).
- There is an important role for the general practitioner who could detect
locally conÍined disease by routine digital rectal examir-r:rrion and / or a
prostate-speciÊc antigen (PSA) determirration.
Chapter 3 gives a review of prostate-speciÊc antigen (PSA), the most
widely used serological marker in prostate cancer, and it's role in evaluating
this disease for diagnosis, clinical staging and prognosis.
Some points of interest:
- Prostate-specific antigen (PSA)
prostat ic  arc inoma-
is currently the marker of choice for
- Various indices of PSA have been developed in an atterrrpt to refine its
sensitivity and improve its clinical value. These include the free to total
ratio of serum PSA level and prostate volume (PSA density), the rate of
change of the PSA level wirh time (PSA velociry), age-clependent PSA
reference ranges, and the proportion offree PSA in serum relative io
total PSA (free ro total PSA rario, f7t PSA ratio). This free to total PSA
ratio is lower in patients with prostate cancer than in those with benign
prostatic hyperplasia.
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Chapter 4 describes the most recent figures of the Dutch Cancer
registratior.r. An increase of prostate cancer is shown ir-r comparison lvith
preceding years (4). In 2001 it is expected that prostate cancer is the rlost
common cancer in men in the Netherlands. Due to the introduction of
prostate-speciÍic antigen (PSA) there is an increase in the incidence of
cancer of the prostate (4,5) and simultar-reously a decrease of primarl.
metastatic prostate cancer in the period 1986-1996 (5). This phenomer-ron
is termed stage-migration. Incidence as well as prevalence are increzrsing.
The population of older men is growing and their age is increasing too.
Patients at first presentation may have cancer of the prostate with
haematogenous and/or lymphogenous metastases. Symptoms in cases
where a metastatic prostate cancer wils not presun.red in the first instance
may be painless lymphomas, pain in the lower back and legs, venous
trombosis in an arm, and headache, vomiting and other neurological
complaints, respectively. The presented patients were fcrund to have
prostate cancer already ciissiminated. After anti-androgen therapv the
symptoms resolved initially. Two men died after 2 years and two patients
are still alive2 and 5 years later. ln men with unexplained complaints, it is
therefore advisable to perform a thorough physical examination, including
digiral rectal examinaticln and a prost:1te specific antigen determin:rtion.
In chapter 5 three young men with metastatic prostate cancer who
presented with complaints of the lower urinary tract are described. Two of
them had a negative famill'history for prostate cancer'. Horvever all the
three had slightly elevated PSA levels but not to the extent expectecl with
metastatic disease. Digital rectal examination was not performed at first
presentation in any of these three patients. The clinical characteristics of
the three selected cases with aggressive prostate cancer sLlpporf our r. ie'"v of
a distinct (tumor) cell change turning the tumor into an aggressivt'and
poorly responding cancer. This emphasizes the need to be aware of the
possibiliry, of highly aggressive and poorly differentiated cancers in voung
patients, with a negative fàmily history and somerimes with minimal
marker elevation. It seems that digital rectal examination is less l ikely to be
performed in younger patients and might have lead to an earlier diagnosis
in these three patients.
The reli:rbil i ty of f irst :rnd second generation PSA irnmunoass:rys i given in
chapter 6. PSA determinations have clinical utility in several phases of
prostate disease including initial screening, diagnosis and treatment
monitoring in prostate cancer management. Numerous commercial assays
became :ivailable to detern.rine sertrm PSA since the introduction of the
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first serologic test. More sensitive assays with a broader working range were
developed, known as 'second generarion' PSA assays. For the majority of
men in this study the first and second generation PSA are equivalent.
This means that on an individual basis it doesn't matrer what type of assay
is applied.
The free-to-total PSA rario appears to be a promising PSA derivative to
decrease unnecessary biopsies because it is based on biological features of
PSA rather than on the subjective and more clinical measures, such as
transrectal ultrasound measured pÍostate volume.
Chapter 7 gives the results ofa study ofPSA and free-to-total PSA ofseven
hundred and sixtcen parienrs referred for prostate evaluation. ln patients
with prostatic disease and with PSA levels in the range 2.0-10.0 trrg/L, the
free-to-total PSA ratio gives a significant improvernent in predicrion of
canceÍ over the total immunoreactive PSA alone.
The relationship between free-to-rotal PSA rario and tumor grade and thus
the ability to predict aggressive versus "insignificant" cancers before
treatment was evaluated. Men with prostate cancer with a poorly
differentiated grade had lower free-to-total PSA ratio's than those with well
differentiated tumors. Recenrly this was confirmed by others (6).
In cltapter 8 a study to diagnose seminal vesicle invasion in prosrare cancer
with two ultrasound-guided biopsies is described. Several prognosric
factors of clinical stage T1.2,.1 prostare cancer with rhe risk of having cancer
growth ir-rto the seminal vesicles are serum PSA concentration, PSA
density, tumor grade from the biopsy specimen and clinical stage. Biopsies
of the seminal vesicle just cephalad to the junction of rhe semir.ral vesicle
and the prostate is an adjunct to identif, T3 rumors with high efEcacy and
Iow morbidity. Seminal vesicle biopsies may provide additionai
information about the clinical stage and thercfore it is useful for the
selection of patients who might obtain good results from radical
prostatectomy (RRP) for prostare cancer, since T2 patients are considered
better candidates for surgery than Tl parienrs. SV biopsy at the junction of
the SV and prostate is accurare for staging with high efEcacy and low
morbidity. To predict SV invasion in prostate cancer paricnrs PSA densrry
was more accurate than PSA or flt PSA ratio. The determination of the f7t
PSA ratio in patients with low - and intermediate PSA levels (c.g <15 StglL)
is not useful to estimate the risk of seminal vesicle involvement. The
combination of serum PSA concentration, PSA density, tumor grade from
the biopsy specimens and clinical stage provides the best prediction of SV
invasion.These parameters are identical to the convenrion:rl predictors of
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pathology after RRP SV biopsies m:r.1,provide additional information, if
one or both basal biopsies are positive, it alters a clinic,rl T,,2 disease in :r T3
Hence SV biopsy is useful to select patients who might obtain good results
from RRP for prostate cancer.
ln cltapter 9 the r.reed for a bone scrrn as a routine staging procedure'"r,as
evaluated in patients with newly diagrrosed prostate cancer in relation rvith
serum prostate speciÍic antigen and alkaline phosphatase (ALP) levels. We
questioned if a reduction of these scans was possible in patients with a lor.v
probabil ity of osseous metastasis ?It was concluded that in newly
cliagnosed and untreated prostate cancer patienrs a bone scan shor-rlcl be
performed in case of-bone pain or ALP levels above 90 U/L. And even in
patients with PSA levels below 201tGlL. and a moderately - (G2) or poorly
difÍèrentiated (G3) tumor grade a bone scan should not be omitted.
In chapter 10 a study of pretreatment levels of urinarv deoxypyriclirroline
(DPD) as potential marker for bone turnover in patients with prostate
carlcer is described. Urinary DPD concentration has been used to estinlate
the degree of bone resorption. In this studywe investigated the usefullness
of prostate-specific antieen (PSA), alkaline phosphatase (ALP) and urinarl,
DPD as markers oÊbone metasrrsis irr patients rvith prrostate cartcer tnd
rhe predictive role oIDPD as bone nrarker, determined at baseline, to
assess osseous metastasis. Urinary DPD, serum ALP and PSA were
evaluated in patients with benign prostatic hyperplasia, with prostate
cancer, of whom 2l hac'l bone metast:rsis and age-matchecl ontrol subjccts.
Prrtients with nervh,diagnosed prostàte cancer and bone metastasis h:rd a
hieher urinary excretion of DPD and a higher serum PSA and ALP than
had patients with BPH and those with prostate cancer but no metastasis.
Receiver operating curve (ROC) analvsis for PSA, ALP and DPD showed
a sigr.rif icant discriminating abil ity fol positive and negirtive bone scans
(p = 0.0684). However, frorn logistic regrcssion of the combinations, onl)'
serum ALP was a significant inde;lendent predictor of bone metastasis in
prrtients with prostate cancer. This study suggests that serum ALP or
urinary DPD are the best predictors of bone metastasis in patients with
Prostate cancer.
In chapter 11 we show the applicabil ity of 1B G needle biopsies to l lssess
telomerase activity in the majority of prostate cancer patients. It is possible
to analyze telomerase activity in very small needle biopsied prostate
sanrples which are appropiate for the TRAP assay. In poorly differentiated
and metastatic prostate cancer we observed relative high levels of
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staging of PSA
telomerase activity, implying it's possible prognostic signiÊcance.
Telomerase activity may be helpful to predict the course of prostate cancer
and may serve as a prognostic factor in small volun-re well differentiated
cancers, allowing guidance for a rnore or less aggressive approach.
To establish accuracy and to distineuish the "relative good fiom the ugly"
prostate cancers further study is needed.
Some investigators have detected circulatir-rg PSA-positive cells by the use
of new molecular biological methods (Z,A). Cett suspensions prepared fronr
peripheral blood samples were stained wirh a monoclonal antibody against
PSA, and then analysed by Ílorv cytometry. A high number oFPSA-positive
cel ls  was re lated [o the metasrat ic  s tarus of  the prostare cancer par ienr .
Using prostate-specific antigen mRNA as a marker for prostirtic epithelial
cells, sensitive techniques have been developed th:rt involve reverse
transcription and polyrnerase chain reaction (RT-PCR) to derect
circul:rt ing turnor cells in the peripheral blood of rnen wirh prost:rte
carcinoma (CaP) (9).In one study (10), the presence of circulating cells
correlated stronglv with the patholoeic stage of the patient. But results of
other studies are contraclictory ( I 1). The clinical applicabil ity of this rest is
not yet fully evaluated. 'Ib identifi' circulating cancer cells at present is not
useful, because the maiority of these cells do not have the abil iq'to iniriarc
a metastatic lesion. As soon as one can predict which patients with
circulating cancer cells will develop metastirsis, then it will be a bcneficial
sraging tool. The negarive RT-PCR test may be clinically relevanr,
suggesting organ-confined disease. This may be valuable in patients who
have a limited lifè expectancy, in this situation "watchftrl rvaiting" can only
be encouraged (12). At the currenr time rnolecular staging is experimental
and not recommended for routine staging (11).
Research in prostate cancer has to be continued to adress three important
aspects.
First, to identify men at high risk who will develop the disease so as ro be
able to offer early intervention and therebl'a chance ofcure. Second, to
identi$, risk factors so :rs to oÍïer recommendations on how to delay the
onset of the disease and, once it is established, to slow the progression of
the disorder (13). Third, to explore the opportunities for rhe prevcnrion of
prostate cancer and to increase the understanding of tumor biology and the
genetic basis of early stages associirted with malignant changes (14).
Molecr-rlar biologists and epiderniologists have to work nrore closelv
together in the hunt for explanations for cancer pathogenesis.
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Conclusions The ideal tumor marker for prostate cancer is not available yet. In prostate
cancer patients a number of serologic markers have been used, over the
years, for diagnosis, staging, prediction ofresponse to therapy, evaluation
of prognosis or in monitoring of the disease status. The usefulness of these
markers for screening purposes of prostate cancer remains to be proven.
Individual tumor markers have been found, in varying degrees of
reliability, for detection of the current or future status of the disease.
Prostate-specific antigen (PSA), a tissue specific marker and not a cancer
specific marker, is now the most widely used biochemical test for the
assessment and follow-up of prostate cancer. It is remarkable how well PSA
functions when compared with the criteria for an ideal marker, nearly at 151
the highest level in terms of performance characteristics for detection,
screening, staging, prognosis and follow-up. In prostate cancer patients
additional prognostic information can be derived from biopsy findings
with important therapeutic implications. This relates also to the need for
reliable markers indicating pathological stage and risk of progression.
Têchnical advances in molecular biology are opening new strategies for
detecting tumor markers providing a field with rapid evolution. Basic
science and clinical investigation must continue in an attempt to find new
ways to enhance the clinical utility of serologic tumor markers in prostate
cancer. New technologies resulted in earlier and more precise diagnosis of
prostate cancet as well as more accurate staging. As a result of this we are
acquiring increasingly the means to relieve much of the suffering associated
with this disease. In the near future, there is a need to develop better
prognostic markers to allow us to distinguish biologically aggressive cancers
from those which are not. In the long term the necessity for the early
diagnosis of prostate canceÍ may give us new opportunities to eliminate
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